Onkologie. 2013:7(2):88-89

Erlotinib in the treatment of advanced pancreatic cancer

Petr Karásek, Beatrix Bencsiková, Jiří Navrátil
Masarykův onkologický ústav Brno, Klinika komplexní onkologické péče, Brno

Pancreatic cancer belongs to the most malignant gastrointestinal tumors. Efforts to improve survival outcomes with gemcitabine-based

combination chemotherapy regimens have been largely disappointing. Among targeted therapies only the EGFR tyrosine kinase inhibitor

erlotinib has shown activity, but clinically relevant in patients developing skin rash.

Keywords: pancreatic cancer, erlotinib, targeted therapy

Published: May 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Karásek P, Bencsiková B, Navrátil J. Erlotinib in the treatment of advanced pancreatic cancer. Onkologie. 2013;7(2):88-89.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Hidalgo M. Pancreatic cancer. N Engl J Med 2010; 362: 1605-1617. Go to original source... Go to PubMed...
    2. Burris HA III, et al. Improvements in survival and clinical benefit with gemcitabine as a first-line therapy for patients with advanced pancreas cancer: a randomised trial. J Clin Oncol 1997; 15: 2403-2413. Go to original source... Go to PubMed...
    3. Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008; 8: 82. Go to original source... Go to PubMed...
    4. Berlin JD, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: ECOG trial. J Clin Oncol 2002; 20: 3270-3275. Go to original source... Go to PubMed...
    5. Moore M, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the NCI of Canada Clinical Trial Group. J Clin Oncol 2007; 25: 1960-1966. Go to original source... Go to PubMed...
    6. Manzano J. Rivera F, Galan M, Valladares M, Pericay C, Mendez MJ, et al. A phase II, open label study to evaluate the relationship between skin rash and survival in patients with unresectable and/or metastatic pancreatic cancer treated with erlotinib combined with gemcitabine. J Clin Oncol 2010; 28(15s): abstract 4094. Go to original source...
    7. Heinemann V, Haas M, Boeck S. Systemic treatment of advanced pancreatic cancer. Cancer Treat Rev. 2012; 38(7): 843-853. Go to original source... Go to PubMed...
    8. Boeck SH, Vehling-Kaiser U, Waldschmidt D, et al. Gemcitabine plus erlotinib GE) followed by capecitabine (C) versus capecitabine plus erlotinib (CE) followed by gemcitabine (G) in advanced pancreatic cancer (APC): A randomized, cross-over phase III trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol 2010; 28(18s) LBA4011. Go to original source...
    9. Verslype C, Verwvenne W, Bennouna J, Humblet Y, Cosaert J, van Cutsem E. Rash as a marker for the efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: Results from the AViTA Study. J Clin Oncol 2009; 27(15s): abstract 4532. Go to original source... Go to PubMed...
    10. Boeck SH, Heinemann V. Anti-epidermal growth factor receptor treatment strategies in advanced pancreatic cancer: success or failure? J Clin Oncol 2011; 29: e70-71; author reply e72-73. Go to original source... Go to PubMed...
    11. Boeck SH, Ormanns S, Laubender RP, Jung A, Siveke JT, Haas M, Neumann J, Vehling-Kaiser U, Winkelmann C, Fischer L, Clemens MR, Gauler TC, Marten A, Klein S, Kojouharoff G, Geissler M, Greten TF, Kirchner T, Heinemann V. Phosphorylated ERK (pERK) as biomarker in patients with advanced pancreatic cancer treated with erlotinib within a randomized phase III trial (AIO-PK0104). J Clin Oncol 2013, Gastrointestinal Cancers Symposium, Vol 31, No 4_suppl (February 1 Supplement), 2013: 189. Go to original source...
    12. Karásek P, Vyzula R, Melichar B, Petruželka L, Petera J, Fínek J, Bartoš J, Kubecová M, Abrahámová J, Janovský V, Bortlíček Z. Erlotinib (Tarceva(R)) v léčbě pokročilého karcinomu pankreatu - výsledky z klinického registru Tarceva Pankreas v České republice. XXXVI. Brněnské onkologické dny, 19.-21. 4. 2012. Číslo abstraktu: 088.

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.